![]() |
![]() |
Legal status
Patent in force
(51) | INT.CL. | C07K 16/28 | (2006.01) |
G01N 33/577 | (2006.01) | ||
G01N 33/574 | (2006.01) |
(11) | Number of the document | 2935329 |
(13) | Kind of document | T |
(96) | European patent application number | 13814812.7 |
Date of filing the European patent application | 2013-12-18 | |
(97) | Date of publication of the European application | 2015-10-28 |
(45) | Date of publication and mention of the grant of the patent | 2020-09-16 |
(46) | Date of publication of the claims translation | 2020-12-10 |
(86) | Number | PCT/US2013/075932 |
Date | 2013-12-18 |
(87) | Number | WO 2014/100079 |
Date | 2014-06-26 |
(30) | Number | Date | Country code |
201261745386 P | 2012-12-21 | US |
(72) |
PIERCE, Robert, H., US
BOURNE, Patricia, US
LIANG, Linda, US
BIGLER, Michael, US
|
(73) |
Merck Sharp & Dohme Corp.,
126 East Lincoln Avenue, Rahway, NJ 07065-0907,
US
|
(74) |
Aušra PAKĖNIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
(54) | Antikūnai, kurie jungiasi prie žmogaus užprogramuoto mirties ligando 1 (PD-L1) |
ANTIBODIES THAT BIND TO HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1) |
Payment date | Validity (years) | Amount | |
2024-11-12 | 12 | 289.00 EUR |
2025-12-18 |